RNV — Renerve Share Price
Last trade - 00:00- AU$14.89m
- AU$8.51m
- AU$0.18m
- 22
- 12
- 36
- 11
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.14 | ||
| Price to Tang. Book | 2.14 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 61.72 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -48.66% | ||
| Return on Equity | -97.81% | ||
| Operating Margin | -1412.71% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | n/a | n/a | n/a | 0.13 | 0.18 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ReNerve Limited is an Australia-based medical device company developing tissue-based products for peripheral nerve repair and replacement and other related soft tissue surgical procedures. It is focused on developing products that accelerate tissue regeneration while preventing scarring and negative inflammatory responses. Its products include NervAlign Nerve Cuff, NervAlign Nerve Graft and NervAlign Bionic Nerve. NervAlign Nerve Cuff is a soft, compatible protective wrap used to protect repaired injured nerves. The product is being developed for the surgical repair of transected (cut) and damaged nerves. NervAlign nerve grafts offers surgeons the ability to repair damaged nerves (neurotmesis) without the need to harvest the sural nerve from the patient. It is developing, NervAlign Bionic Nerve, a combination polymer technology and its nerve graft to produce a replacement nerve that contains shaped ionic polymers which would enable the stimulation of the distal end of a nerve injury.
Directors
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 16th, 2016
- Public Since
- November 26th, 2024
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 141,837,806
- Address
- 157 Heidelberg Road, Northcote, 3070
- Web
- https://renerve.com.au/
- Phone
- Auditors
- William Buck Audit (Vic) Pty Ltd
Similar to RNV
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
Aroa Biosurgery
Australian Stock Exchange - SEATS
FAQ
As of Today at 22:54 UTC, shares in Renerve are trading at AU$0.11. This share price information is delayed by 15 minutes.
Shares in Renerve last closed at AU$0.11 and the price had moved by over the past 365 days. In terms of relative price strength the Renerve share price has matched the ASX All Ordinaries Index by over the past year.
There is no consensus recommendation for this security.
Find out moreRenerve does not currently pay a dividend.
Renerve does not currently pay a dividend.
Renerve does not currently pay a dividend.
To buy shares in Renerve you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.11, shares in Renerve had a market capitalisation of AU$14.89m.
Here are the trading details for Renerve:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: RNV
Based on an overall assessment of its quality, value and momentum Renerve is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Renerve. Over the past six months, its share price has matched the ASX All Ordinaries Index by .
As of the last closing price of AU$0.11, shares in Renerve were trading -25.2% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Renerve PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.11.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Renerve's directors